Be part of the knowledge.™
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Upcoming Events

Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

Join our live broadcast to redefine HR+/HER2-expressing mBC treatment via cutting-edge data on ADCs, sequencing therapies, and AE management strategies.

Live Broadcast
1.00 available credits
Information
March 28, 2025
03:00 PM - 04:00 PM EDT
Virtual
ReachMD Healthcare Image

This broadcast will start in exactly:

  • 0

    Day(s)

  • 0

    Hour(s)

  • 0

    Minute(s)

  • 0

    Second(s)

ENROLL
Details
Presenters

  • Overview

    This educational activity will explore emerging data and clinical guidelines for accurately defining HER2 status in patients with metastatic breast cancer (mBC), improving identification for targeted ADC treatments. We will evaluate the efficacy of ADCs in HR+ mBC across the HER2-expression continuum, discuss the impact of recent clinical trial results on ADC selection and sequencing, and develop team-based strategies to manage potential treatment-related AEs. Engage with experts to refine your approach to treating patients with HR+/HER2-expressing advanced breast cancer.

  • Program Schedule*

    • Pre-Assessment Questions
    • Navigating HER2 Expression in Breast Cancer: Applying Emerging Data and Guidelines for Targeted ADC Treatment Eligibility
    • ADC Efficacy in HR+ Metastatic Breast Cancer: Insights Across the HER2-Expression Continuum  
    • Sequencing Strategies in HR+ Metastatic Breast Cancer: Leveraging ADCs Across the HER2 Continuum
    • Monitoring and Managing Adverse Events: Navigating ADCs in Breast Cancer Treatment
    • Case-Based Learning Lab  
    • Conclusion/Q&A/Discussion
    • Post-Assessment Questions 

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
    Adam Brufsky, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consultant; AstraZeneca Pharmaceuticals LP, Agendia, Blueprint Medicines, Caris , Daiichi Sankyo, Inc., Epic Biosciences, Genentech/Roche, Gilead, Lilly , Merck & Co., Inc., Myriad Genetics, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., PUMA , Sanofi, SeaGen & Tempus. Research grant; Agendia.  

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Bing-E Xu, PhD; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply emerging data and guideline recommendations to accurately define HER2 status in breast cancer patients, thereby improving the identification of patients eligible for appropriate targeted ADC treatments
    • Evaluate recent and emerging data on the efficacy of ADCs in terms of progression-free survival, objective response rate, and quality of life for patients with HR+ mBC across the HER2-expression continuum
    • Evaluate how recent clinical trial results impact ADC selection and sequencing for patients with metastatic breast cancer across the HER2-expression continuum
    • Employ team-based strategies to identify, mitigate, and manage potential treatment-related AEs in patients receiving ADC therapies for mBC

  • Target Audience

    This initiative is designed for US community-based medical oncologists, pathologists/lab professionals, oncology nurse practitioners, physician assistants, oncology nurses, nurse navigators, pharmacists, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with HR+ HER2-expressing (HER2+/HER2-low/HER2-ultra-low) mBC.

  • Accreditation and Credit Designation Statements


    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians 
    AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants 
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until 03/21/2025. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists 
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-24-052-L01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Credit Designation for Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program. 

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc. 

  • Disclaimer

    Disclaimer         
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use                                     
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information.

  • AXIS Contact Information

    AXIS Contact Information
    For information about the certification of this activity, please contact AXIS at info@axismeded.com.

    There is no fee for this educational activity.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters
Recommended

  • Overview

    This educational activity will explore emerging data and clinical guidelines for accurately defining HER2 status in patients with metastatic breast cancer (mBC), improving identification for targeted ADC treatments. We will evaluate the efficacy of ADCs in HR+ mBC across the HER2-expression continuum, discuss the impact of recent clinical trial results on ADC selection and sequencing, and develop team-based strategies to manage potential treatment-related AEs. Engage with experts to refine your approach to treating patients with HR+/HER2-expressing advanced breast cancer.

  • Program Schedule*

    • Pre-Assessment Questions
    • Navigating HER2 Expression in Breast Cancer: Applying Emerging Data and Guidelines for Targeted ADC Treatment Eligibility
    • ADC Efficacy in HR+ Metastatic Breast Cancer: Insights Across the HER2-Expression Continuum  
    • Sequencing Strategies in HR+ Metastatic Breast Cancer: Leveraging ADCs Across the HER2 Continuum
    • Monitoring and Managing Adverse Events: Navigating ADCs in Breast Cancer Treatment
    • Case-Based Learning Lab  
    • Conclusion/Q&A/Discussion
    • Post-Assessment Questions 

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months:
    Adam Brufsky, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consultant; AstraZeneca Pharmaceuticals LP, Agendia, Blueprint Medicines, Caris , Daiichi Sankyo, Inc., Epic Biosciences, Genentech/Roche, Gilead, Lilly , Merck & Co., Inc., Myriad Genetics, Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., PUMA , Sanofi, SeaGen & Tempus. Research grant; Agendia.  

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Bing-E Xu, PhD; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Melissa Duffy, PA-C; and Adrienne N. Nedved, PharmD, MPA, BCOP hereby state that they do not have any financial relationships or relationships with any ineligible company of in any amount during the past 24 months. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck during the past 24 months.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Apply emerging data and guideline recommendations to accurately define HER2 status in breast cancer patients, thereby improving the identification of patients eligible for appropriate targeted ADC treatments
    • Evaluate recent and emerging data on the efficacy of ADCs in terms of progression-free survival, objective response rate, and quality of life for patients with HR+ mBC across the HER2-expression continuum
    • Evaluate how recent clinical trial results impact ADC selection and sequencing for patients with metastatic breast cancer across the HER2-expression continuum
    • Employ team-based strategies to identify, mitigate, and manage potential treatment-related AEs in patients receiving ADC therapies for mBC

  • Target Audience

    This initiative is designed for US community-based medical oncologists, pathologists/lab professionals, oncology nurse practitioners, physician assistants, oncology nurses, nurse navigators, pharmacists, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with HR+ HER2-expressing (HER2+/HER2-low/HER2-ultra-low) mBC.

  • Accreditation and Credit Designation Statements


    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

    Credit Designation for Physicians 
    AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Physician Assistants 
    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits.  Approval is valid until 03/21/2025. PAs should only claim credit commensurate with the extent of their participation.

    Credit Designation for Pharmacists 
    This application-based activity is approved for 1.0 contact hour of continuing pharmacy education JA4008106-0000-24-052-L01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    Credit Designation for Laboratory Professionals
    This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology as meeting the criteria for 1.0 CMLE credit. ASCP CMLE credits are acceptable to meet the continuing education requirement for the ASCP Board of Registry Certification Maintenance Program. 

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc. 

  • Disclaimer

    Disclaimer         
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Disclosure of Unlabeled Use                                     
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications.The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings,and other, related information.

  • AXIS Contact Information

    AXIS Contact Information
    For information about the certification of this activity, please contact AXIS at info@axismeded.com.

    There is no fee for this educational activity.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Recommended

Schedule14 Mar 2025
PrevNext

Program Chapters

Segment Chapters

Playlist:

Recommended